Abstract
Although primary angioplasty is the preferred treatment modality for acute myocardial infarction (MI), in centers without primary angioplasty (PA) capabilities, fibrinolytic therapy is still the recommended alternative. Combined fibrinolytic (CF) therapy has been shown to improve infarct-related artery (IRA) patency before PA and may improve safety of rescue angioplasty (RA). A randomized multicenter pilot study was conducted in the Asia-Pacific region to compare the safety and efficacy between primary angioplasty with adjunct abciximab vs combined fibrinolytic (alteplase and abciximab) therapy with or without rescue angioplasty for the treatment of AMI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
